Adam Pellegrini, former CEO of Kaia Health and Jasper Health, is TytoCare’s new CEO, and Greg Orr, former VP of digital health at Walgreens, is the company’s new COO.
TytoCare, a company that provides AI-enabled remote physical examination technology for virtual healthcare, closed an oversubscribed $25 million-plus growth round and announced the appointments of a new chief executive officer and chief operating officer.
Insight Partners led the growth round, with participation from existing strategic investors OliveTree, HOOP, Qumra Capital, Qualcomm Ventures, OrbiMed and others.
Adam Pellegrini is the company’s new CEO, replacing Dedi Gilad, who cofounded TytoCare and served as CEO for 13 years. Gilad remains on the company’s team as chairman, according to his LinkedIn profile.
Pellegrini formerly held the role of CEO and board member of digital oncology platform Jasper Health and CEO of digital musculoskeletal care company Kaia Health, which was acquired by Sword Health for $285 million in January. He subsequently became an executive in residence at Sword Health and is a board member of brain-data software company Rune Labs.
Additionally, Greg Orr has been appointed as TytoCare’s new chief operating officer. Orr formerly held the role of vice president of digital health at Walgreens and chief operating officer of Jasper Health.
WHAT IT DOES
New York-based TytoCare offers FDA-cleared and CE-marked AI-enabled devices that allow for remote examination for areas like the ears, throat, heart, lungs, skin, abdomen, body temperature and heart rate during virtual care visits.
The data from the devices is transmitted to a clinician either live during a video visit or asynchronously, where a patient performs guided exams and sends the results for later review.
The company said it will use the funds to expand its AI clinical algorithms, deepen its payer and health system partnerships, and accelerate go-to-market efforts in areas including cardiometabolic patients and individuals undergoing cancer treatment and post-acute care transitions.
TytoCare said Pellegrini will lead the company’s expansion of its AI-assisted exam technology into clinical workflows across health systems, specialty care programs and payer-supported chronic disease management.
“The convergence of a clinically validated exam device, AI-powered diagnostic algorithms and the urgent demand from health systems for real clinical intelligence at the point of virtual care is an extraordinary and rare combination,” Pellegrini said in a statement. “TytoCare has built the foundational infrastructure for the next generation of intelligent remote care, and I could not be more energized to lead this next chapter.”
MARKET SNAPSHOT
In May, TytoCare received FDA De Novo classification for its Tyto Insights for ENT Suite, an AI-enabled tool that analyzes otoscopy videos. The tool is designed to detect bulging of the eardrum during video recordings captured with the company’s digital otoscope.
Last year, the company announced a partnership with virtual care provider Teladoc Health to integrate its Home Smart Clinic handheld device with Teladoc’s primary care programs to collect diagnostic insights at home. The integration was set to roll out in 2026.
In 2024, TytoCare announced five healthcare systems adopted its school health initiative, bringing its primary and urgent care services to more than 2,500 schools in 31 states.
The year before, TytoCare secured $49 million in funding and received FDA clearance for its clinical decision-support software, Tyto Insights for Wheeze Detection.
The software uses the company’s stethoscope to evaluate lung sounds and identify recordings that suggest wheezing in adults and children ages two and older. The same software received a European CE Mark in 2022.
It also announced an exclusive partnership with Idaho-based St. Luke’s Health System to provide virtual care services to the care provider’s members and employees.
The company secured $50 million in Series D funding in 2021 and $50 million in an oversubscribed round in 2020.
